What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets”In the company’s words, NCT05918861 on ClinicalTrials.gov
- Tested for
- Acute Coronary Syndrome
- Main trialPhase 3
- “This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following…”In the company’s words, NCT05918861 on ClinicalTrials.gov
Other drugs for Acute Coronary Syndrome
- VicagrelJiangsu vcare pharmaceutical technology co., LTD · Phase 3
- OrticumabAbcentra · Phase 2
- CG-0255Shanghai CureGene Pharmaceutical Co., Ltd. · Phase 1
- InclisiranNovartis · Marketed (Phase 4 trial)
Coming up1
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | |
| Phase 3Completed | Oct 2021 | Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS | |
| Phase 2Completed | 17 May 2021 | Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026